Revised UK guidelines for the management of cutaneous melanoma 2010

Marsden, Jerry; Newton-Bishop, Julia; Burrows, Lara J.; Cook, Martin; Corrie, Pippa; Cox, Neil; Gore, Martin; Lorigan, Paul; MacKie, Rona M.; Nathan, Paul; Peach, Howard; Powell, Barry; Walker, Christy

doi:10.1016/j.bjps.2010.07.006

Cited by 171 publications

(135 citation statements)

References 128 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the efficacy of reducing population exposure to the sun through public education campaigns, which originated in Australia, has not been demonstrated (Whiteman et al, 2008). Statements about the benefits of sunshine for vitamin D levels v (Marsden et al, 2010) and notions about the outdoors as healthy, documented in the following data analysis, may cause further confusion about the status of a risk factor, the predictive power of which has been overstated.…”

Section: Impact Of Time-lapses Prior To Treatmentmentioning

confidence: 99%

“…Thus, the starting point for framing previous risk management was the taken-for-granted acceptance of a medically 'encoded' but problematic set of beliefs (Alaszewski, 2010, p. 134) about time and risk. At the clinical sharp end of expert summaries (The Melanoma Taskforce, 2012) and clinical guidelines (Marsden et al, 2010), uncertainties tend to be bracketed out, with doubts tacitly suppressed through an unspoken collective process of deletion (Law, 1996). Hence, practice is predicated on acceptance of a package of prevailing risk wisdom as 'scientifically' proven.…”

mentioning

confidence: 99%

See 1 more Smart Citation

‘I am not someone who gets skin cancer’: risk, time and malignant melanoma

Topping

Nkosana-Nyawata

Heyman

2013

Health, Risk & Society

View full text Add to dashboard Cite

ABSTRACT'Delay' is a term used in the cancer literature since the 1930s to describe the period between self-detection of a concerning sign of possible disease and presentation to a health professional. This linguistic choice carries an implication of blame for apparent failure to manage a risk appropriately, drawing attention away from the contemporaneous perspectives of those who respond to suspicious indicators more or less quickly. We present findings from a grounded theory study of accounts given by 45 patients about their slower or quicker journeys to a diagnosis of cutaneous 2 malignant melanoma, a cancer which can 'hide in plain sight'. There has been little research exploring in qualitative detail patients' perspectives on their decision-making about what subsequently turn out to have been signs of this most risky of skin cancers.The findings frame referral time-lapses in terms of normalisation of symptoms, sometimes buttressed by reassurance derived from health promotion messages, disconfirmation of patients' concerns by their general practitioners and prioritisation of other life concerns. We argue that a shared sense of urgency surrounding melanoma self-referral derives from a clinical representation of current knowledge which conceals numerous evidential uncertainties.

show abstract

Section: Impact Of Time-lapses Prior To Treatmentmentioning

confidence: 99%

mentioning

confidence: 99%

‘I am not someone who gets skin cancer’: risk, time and malignant melanoma

Topping

Nkosana-Nyawata

Heyman

2013

Health, Risk & Society

View full text Add to dashboard Cite

show abstract

“…[2][3][4] Primary care excision biopsy for diagnostic purposes is discouraged because 'clinicopathological correlation is vital for diagnostic accuracy, which in turn determines prognosis and defines adjuvant treatment options and because diagnostic surgery requires specialist training'. 2 Indeed, any patient receiving their initial diagnostic biopsy in UK primary care is commonly perceived to have been mismanaged. 5 This is concerning, when it is considered that up to 20% of melanomas diagnosed in the UK have been first biopsied in primary care.…”

Section: Introductionmentioning

confidence: 99%

Mortality and morbidity after initial diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care

Murchie¹,

Raja²,

Lee³

et al. 2013

Br J Gen Pract

View full text Add to dashboard Cite

BackgroundCurrent UK melanoma guidelines do not support the initial diagnostic excision biopsy of pigmented lesions in primary care, although this is standard in other countries such as Australia. Previous research in Northeast Scotland found that initial diagnostic excision biopsies in primary care that prove to be melanoma were no more likely to be incomplete than those performed in secondary care, but data on longer-term outcomes were not available.

show abstract

“…These cells were grown with DMEM (Biological Industries, Beit Haemek, Israel) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, Carlsbad, CA), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM Lglutamine all from Biological Industries. Cells were grown at 37 ºC in a 5% CO 2 atmosphere.…”

mentioning

confidence: 99%

Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells

et al. 2013

View full text Add to dashboard Cite

Melanoma is one of the most aggressive types of skin cancer and its incidence rate is still increasing. All existing treatments are minimally effective. Consequently, new therapeutic agents for melanoma treatment should be developed. The DM-1 compound is a curcumin analog that possesses several curcumin characteristics, such as antiproliferative, antitumor and antimetastatic properties. The aim of this study was to evaluate the different signaling pathways involved in the cytotoxic effect of DM-1 on melanoma cells.The apoptotic process and cytoskeletal changes were evaluated by immunoblotting and immunofluorescence, respectively, in melanoma cells.After DM-1 treatment, SK-MEL-5 melanoma cells showed actin filaments disorganization with spicules formation throughout the cytoskeleton and significant reduction of focal adhesion as well as they were present only at cell extremities, conferring a poor connection between the cell and the substrate. Besides this, there was significant filopodium retraction and loss of typical cytoskeleton scaffold. These modifications contributed to cell detachment followed by cell death.Furthermore, DM-1-induced apoptosis was triggered by multiple Bcl-2 proteins involved in both the extrinsic and the intrinsic apoptotic pathways. SK-MEL-5 cells showed a death mechanism mainly by Bcl-2/Bax ratio decrease, whereas A375 cells presented apoptosis induction by Mcl-1 and Bcl-xL downregulation. In SK-MEL-5 and A375 melanoma cells, there were a significant increase in the active form of caspase 9 and the inactive form of the effector caspase 3 was decreased in both cell lines. Expression of cleaved Parp was increased after DM-1 treatment in these melanoma cell lines, demonstrating 2 that the apoptotic process occurred. Altogether, these data elucidate the cellular and molecular mechanisms involved in the cytotoxicity induced by the antitumor agent DM-1 in melanoma cells.

show abstract

Revised UK guidelines for the management of cutaneous melanoma 2010

Cited by 171 publications

References 128 publications

‘I am not someone who gets skin cancer’: risk, time and malignant melanoma

‘I am not someone who gets skin cancer’: risk, time and malignant melanoma

Mortality and morbidity after initial diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care

Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells

Contact Info

Product

Resources

About